Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
CLEVELAND , Nov. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference .     From November 23 to December 3, 2020 , a fireside chat recording will be available for registered attendees via the Piper
Toggle Summary Amsterdam University Medical Centers Treats 1,000th Patient with MRIdian SMART MRI-Guided Radiation Therapy
Amsterdam UMC reaches treatment milestone while establishing key clinical evidence in tough-to-treat cancer including pancreas, prostate, lung, liver, and kidney CLEVELAND , Nov. 12, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University
Toggle Summary Leading Academic Clinical Training Hospital, Universitair Ziekenhuis Brussels, Purchases ViewRay's MRIdian Linac
Universitair Ziekenhuis Brussels in Belgium Aims to Begin MRIdian Patient Treatments in 2021 CLEVELAND , Nov. 10, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Universitair Ziekenhuis Brussels has purchased a MRIdian ®  Linac MRI-Guided Therapy System, a cutting-edge
Toggle Summary ViewRay Reports Third Quarter 2020 Results
CLEVELAND , Nov. 5, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2020 .     Third Quarter 2020 Highlights: Total revenue of $10.1 million , primarily from one revenue unit, compared to $20.9 million ,

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Financial Events
More events are coming soon.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449

In Need of Customer Support? Contact

  Language Select